ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $42.21 billion. The enterprise value is $41.85 billion.
| Market Cap | 42.21B |
| Enterprise Value | 41.85B |
Important Dates
The last earnings date was Thursday, July 31, 2025, after market close.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
ResMed has 146.41 million shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | 146.41M |
| Shares Outstanding | 146.41M |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -0.12% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 74.05% |
| Float | 145.49M |
Valuation Ratios
The trailing PE ratio is 30.31 and the forward PE ratio is 26.44. ResMed's PEG ratio is 1.92.
| PE Ratio | 30.31 |
| Forward PE | 26.44 |
| PS Ratio | 8.22 |
| Forward PS | 7.56 |
| PB Ratio | 7.07 |
| P/TBV Ratio | 17.18 |
| P/FCF Ratio | 25.40 |
| P/OCF Ratio | 24.10 |
| PEG Ratio | 1.92 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.50, with an EV/FCF ratio of 25.19.
| EV / Earnings | 29.88 |
| EV / Sales | 8.13 |
| EV / EBITDA | 22.50 |
| EV / EBIT | 24.80 |
| EV / FCF | 25.19 |
Financial Position
The company has a current ratio of 3.44, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.44 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.45 |
| Debt / FCF | 0.51 |
| Interest Coverage | 2,884.43 |
Financial Efficiency
Return on equity (ROE) is 25.86% and return on invested capital (ROIC) is 16.80%.
| Return on Equity (ROE) | 25.86% |
| Return on Assets (ROA) | 14.02% |
| Return on Invested Capital (ROIC) | 16.80% |
| Return on Capital Employed (ROCE) | 23.58% |
| Revenue Per Employee | $515,664 |
| Profits Per Employee | $140,353 |
| Employee Count | 9,980 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.09 |
Taxes
In the past 12 months, ResMed has paid $276.84 million in taxes.
| Income Tax | 276.84M |
| Effective Tax Rate | 16.50% |
Stock Price Statistics
The stock price has increased by +34.30% in the last 52 weeks. The beta is 0.77, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | +34.30% |
| 50-Day Moving Average | 262.64 |
| 200-Day Moving Average | 242.45 |
| Relative Strength Index (RSI) | 67.81 |
| Average Volume (20 Days) | 1,177,688 |
Short Selling Information
The latest short interest is 9.02 million, so 6.16% of the outstanding shares have been sold short.
| Short Interest | 9.02M |
| Short Previous Month | 10.13M |
| Short % of Shares Out | 6.16% |
| Short % of Float | 6.20% |
| Short Ratio (days to cover) | 9.55 |
Income Statement
In the last 12 months, ResMed had revenue of $5.15 billion and earned $1.40 billion in profits. Earnings per share was $9.51.
| Revenue | 5.15B |
| Gross Profit | 3.09B |
| Operating Income | 1.69B |
| Pretax Income | 1.26B |
| Net Income | 1.40B |
| EBITDA | 1.86B |
| EBIT | 1.69B |
| Earnings Per Share (EPS) | $9.51 |
Balance Sheet
The company has $1.21 billion in cash and $851.81 million in debt, giving a net cash position of $357.64 million or $2.44 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 851.81M |
| Net Cash | 357.64M |
| Net Cash Per Share | $2.44 |
| Equity (Book Value) | 5.97B |
| Book Value Per Share | 40.77 |
| Working Capital | 2.49B |
Cash Flow
In the last 12 months, operating cash flow was $1.75 billion and capital expenditures -$89.87 million, giving a free cash flow of $1.66 billion.
| Operating Cash Flow | 1.75B |
| Capital Expenditures | -89.87M |
| Free Cash Flow | 1.66B |
| FCF Per Share | $11.35 |
Margins
Gross margin is 59.99%, with operating and profit margins of 32.79% and 27.22%.
| Gross Margin | 59.99% |
| Operating Margin | 32.79% |
| Pretax Margin | 32.60% |
| Profit Margin | 27.22% |
| EBITDA Margin | 36.15% |
| EBIT Margin | 32.79% |
| FCF Margin | 32.29% |
Dividends & Yields
This stock pays an annual dividend of $2.40, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | $2.40 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | 11.17% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 23.03% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 0.97% |
| Earnings Yield | 3.32% |
| FCF Yield | 3.94% |
Analyst Forecast
The average price target for ResMed is $276.82, which is -3.98% lower than the current price. The consensus rating is "Buy".
| Price Target | $276.82 |
| Price Target Difference | -3.98% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 8.42% |
| EPS Growth Forecast (5Y) | 10.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.06 and a Piotroski F-Score of 7.
| Altman Z-Score | 12.06 |
| Piotroski F-Score | 7 |